Melbourne-based women’s health company Ovum has secured AUD $4 million in seed funding to expand its AI-led platform and build a longitudinal women’s health dataset. The raise comes around a year after the company’s A$1.7 million pre-seed round, with Ovum stating that its valuation has since tripled. Founded by doctor Ariella Heffernan-Marks, the company is positioning its technology as a response to persistent gaps in women’s healthcare data, diagnosis and support.
Funding and Expansion Plans
The seed round was led by Admiralty Capital Group, with participation from Antler, Giant Leap, Aviron Investments, Foggy Valley Aotearoa, Brisbane Angels and Think & Grow. LaunchVic also increased its investment through The Alice Anderson Fund. Ovum said the capital will support team growth and the continued development of its women’s health data infrastructure.
Ovum is developing an AI-powered health journal that allows users to record symptoms, lifestyle information, biometrics, reproductive health changes, medications, appointments and medical reports. The platform uses this information to identify patterns over time, create health summaries and suggest questions that users can raise during clinical consultations. The company says this approach is designed to help women better understand their health and advocate more effectively within healthcare settings.
Early User Growth
Since launching in August 2025, Ovum says it has recorded more than 20,000 downloads, 60,000 women’s health data insights and over 113,000 AI health conversations. The company also reports monthly growth of around 30%, with users ranging in age from 15 to 84. These figures indicate growing interest in digital health tools that can bring together information often fragmented across different providers, appointments and life stages.
Ovum has also begun establishing commercial partnerships across healthcare, fitness and workplace wellbeing. The company signed Medibank, Australia’s largest private health insurer, before its product launch and has since partnered with Fernwood Fitness, Sweat and Menopause Friendly Australia. It is also running a pilot with Australian Red Cross Lifeblood as it seeks to address the estimated A$150 billion in annual productivity losses linked to women reducing or leaving work for health-related reasons.
Privacy and Data Infrastructure
Privacy and consent are central to Ovum’s data strategy, according to the company. Ovum says user information is encrypted and protected through standards including GDPR and SOC 2 Type II, while anonymised data is only used with user consent. The company reports that 83% of users have opted to share anonymised data that could contribute to future research into women’s health conditions, treatment and care.
Admiralty Capital Group founding partner Amanda Andriano said the company is addressing a problem that has long been accepted despite its broad social and economic consequences. She said Ovum combines a large market opportunity with a founder whose medical and personal experience gives her a strong understanding of the issue. The investor believes this combination could support the development of a company with international relevance in women’s health.
Clinical Research and Access
Earlier this year, Ovum began clinical trials with St George Hospital and the Royal Hospital for Women. The studies are examining how women manage their health, which digital tools they use and how AI may improve health confidence, self-advocacy and continuity of care. Ovum describes the research as Australia’s first clinical assessment of AI as a preventative health tool designed specifically for women.
The company also operates a Pay It Forward model that allows users to gift platform access to other women. Through this initiative, memberships are being provided to women connected with the Royal Hospital for Women and Pink Elephants who face financial or access barriers. Ovum said the model reflects its broader goal of making women’s health support more accessible while building a more representative data foundation.
Ovum’s seed funding provides additional resources to convert its early consumer traction into a larger health technology platform spanning personal care, clinical research and workplace partnerships. The company’s strategy combines AI-led health tracking with privacy-focused data collection and initiatives aimed at improving women’s ability to navigate healthcare systems. Its progress will now depend on whether it can translate user growth, enterprise partnerships and clinical research into measurable improvements in women’s health outcomes.